29
total announcements
JAGSNPHARM.NS · 15 min delayed
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has submitted a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, stating that the promoters have not created any encumbrance over the shares of the company as on March 31, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has announced the acquisition of an 85% stake in Aequitas Healthcare Private Limited, a pharmaceutical company focused on sale and distribution of pharmaceutical products to hospitals, for Rs. 20.8 crores. The acquisition marks Jagsonpal's strategic entry into the hospital segment and is expected to strengthen its presence in India's growing healthcare ecosystem.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals has announced the acquisition of 85% stake in Aequitas Healthcare Private Limited, a pharmaceutical company, for INR 20.8 Crore. The acquisition is expected to be completed by 15th July 2026 and is aimed at gaining access to the hospital channel and institutional doctor network for the Company’s products.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited will remain closed for Designated Persons and their immediate relative(s) from July 01, 2026, and will open 48 hours after the declaration of unaudited financial results for the quarter ended on June 30, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has appointed Mr. Anil Kumar Matai as an Independent Director on its Board, bringing over three decades of experience in the pharmaceutical and healthcare sectors.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange about the appointment of Mr. Anil Kumar Matai as an Independent Director, effective June 25, 2026, for a period of 5 years, subject to shareholder approval.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has appointed Mr. Anil Kumar Matai as an Independent Director, effective June 25, 2026, for a period of 5 years, subject to shareholder approval.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the appointment of Mr. Anil Kumar Matai as a Non-Executive Independent Director of the company, effective June 25, 2026.